MONROVIA, Calif., Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Xencor at a price to the public of $24.00 per share. The gross proceeds to Xencor from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xencor, were approximately $126.5 million. Xencor anticipates using the net proceeds from the offering for working capital and general corporate purposes, including additional investments in advancing its lead compound XmAb®5871 through later stages of clinical development and additional investment in its immune-oncology pipeline and technology.
Leerink Partners acted as sole book-running manager in the offering. Canaccord Genuity and Wedbush PacGrow acted as co-managers in the offering.